[PDF][PDF] 肝移植术后中远期巨细胞病毒的感染情况及诊治

黄云帆, 刘大平, 陈虹, 王旭, 范铁艳 - 实用器官移植电子杂志, 2018 - zqenorth.com.cn
treatment of mid-long-term cytomegalovirus (CMV)infection after liver transplantation. Methods
The patients with mid-long-term cytomegalovirus infection … indirect effects of CMV infection

肝移植后巨细胞病毒感染: 对排斥反应与移植物的影响

黄云帆, 陈虹, 王旭, 范铁艳 - 中国组织工程研究, 2014 - cjter.com
valganciclovir and intravenous ganciclovir are safe, feasible options for preemptive treatment
of cytomegalovirus infection … of cytomegalovirus infection in the long-term outcome of renal …

[HTML][HTML] 肾移植术后巨细胞病毒感染的预防

王垒, 黄康, 彭贵主, 叶啟发 - 武汉大学学报(医学版), 2017 - xml-data.org
… In this review, we will summarize the risk factors of CMV infection… 已不再应用于临床抗CMV治疗
;② 更昔洛韦(ganciclovir, GCV),该药… Randomized trial of valganciclovir versus valacyclovir

[HTML][HTML] 先天性巨细胞病毒感染的母婴防治进展

徐雯芳, 袁天明 - 中国当代儿科杂志, 2018 - zgddek.com
… to the early diagnosis of congenital CMV infection. In addition to short-… treatment with
ganciclovir, long-term treatment with oral valganciclovir is safe for symptomatic congenital CMV

肾移植后并发卡氏肺孢子虫肺炎36 例资料回顾

刘永光, 郭颖, 李民, 岳良升, 李留洋, 赵明 - 中国组织工程研究, 2010 - cjter.com
… , previous rejection therapy, cytomegalovirus infection[5]. In … after transplantation, with
ganciclovir or valganciclovir[16]. … Section IV: Long-term management of the transplant recipient…

[PDF][PDF] 更昔洛韦联合大剂量丙种球蛋白治疗婴儿巨细胞病毒性肝炎的疗效观察

邢芳华, 王荣坤, 邢舒旺, 邓武兴, 陈洁 - 现代生物医学进展, 2018 - biomed.cnjournals.com
… effect of ganciclovir combined with high dose intravenous … ing of ganciclovir for postnatal
cytomegalovirus infection in an … vaccination in elderly residents of long-term care facilities[J]. …

[PDF][PDF] 缩宫素联合卡前列素氨丁三醇对产后出血患者凝血功能及血流动力学的影响

杨青青, 田阗, 郑泽玉, 蒲元芳, 邬洪明… - 现代生物医学 …, 2018 - biomed.cnjournals.com
… Efficacy of ganciclovir in prevention of CMV infection after D+/R+ … vaccination in elderly
residents of long-term care facilities[J]. … Intravenous immunoglobulin treatment for secondary …

[PDF][PDF] 心脏移植术后并发症及研究现状

李雨琪, 张海波, 孟旭 - 实用器官移植电子杂志, 2017 - syqgyz.magtechjournal.com
… 伐昔洛韦是能减少CMV 感染和排斥反应的 新型用药.预防性应用伐昔洛韦可减少CMV 发病率
, 从22% 降至2%.高剂量伐昔洛韦(8 g/d)被证明 有效[60],但是38% 的患者由于发生神经系统并发…